Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 6/20 | 0.48 |
| ▸ | CTSK | P43235 | 5/20 | 0.43 |
| ▸ | CCR6 | P51684 | 1/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1554884 | 1.00 | SYK (0.48) | SYKBACE1CTSKCCR6PAX8 | |
| SCHEMBL4896500 | 0.97 | SYK (0.47) | SYKBACE1CTSKCCR6PAX8 | |
| SCHEMBL4891550 | 0.94 | SYK (0.50) | SYKBACE1CTSKATMCTSL | |
| SCHEMBL15003939 | 0.92 | SYK (0.51) | SYKBACE1CTSKCTSLCTSS | |
| SCHEMBL15316174 | 0.92 | SYK (0.51) | SYKBACE1CTSKCTSLCTSS | |
| SCHEMBL14256999 | 0.89 | SYK (0.52) | SYKBACE1CTSKATMCTSL | |
| SCHEMBL14990389 | 0.86 | BACE1 (0.46) | SYKBACE1CTSKATMMAPT | |
| SCHEMBL5729333 | 0.86 | SYK (0.51) | SYKBACE1CTSKATMCTSL | |
| SCHEMBL4890767 | 0.86 | BACE1 (0.44) | SYKBACE1CTSKATMMAPT | |
| SCHEMBL8693569 | 0.85 | SYK (0.50) | SYKBACE1CTSKATMCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9540344-B2 | Production method for isoquinoline derivatives and salts thereof | KOWA CO., LTD. (JP) | 2017-01-10 | — | — | US | disclosed |
| US-9540344-B2 | Production method for isoquinoline derivatives and salts thereof | KOWA CO., LTD. (JP) | 2017-01-10 | — | — | US | disclosed |
| US-9045460-B2 | Production method for isoquinoline derivatives and salts thereof | KOWA CO., LTD. (JP) | 2015-06-02 | — | — | US | disclosed |
| US-9045460-B2 | Production method for isoquinoline derivatives and salts thereof | KOWA CO., LTD. (JP) | 2015-06-02 | — | — | US | disclosed |
| US-20150087824-A1 | NOVEL PRODUCTION METHOD FOR ISOQUINOLINE DERIVATIVES AND SALTS THEREOF | KOWA CO., LTD. (JP) | 2015-03-26 | — | — | US | disclosed |
| US-20150087824-A1 | NOVEL PRODUCTION METHOD FOR ISOQUINOLINE DERIVATIVES AND SALTS THEREOF | KOWA CO., LTD. (JP) | 2015-03-26 | — | — | US | disclosed |
| EP-2818463-A1 | Production method of 1,4-diazepane derivatives | Kowa Co., Ltd. (JP) | 2014-12-31 | — | — | EP | disclosed |
| EP-2610252-A1 | NOVEL PRODUCTION METHOD FOR ISOQUINOLINE DERIVATIVES AND SALTS THEREOF | Kowa Co., Ltd. (JP) | 2013-07-03 | — | — | EP | disclosed |
| US-20130144054-A1 | NOVEL PRODUCTION METHOD FOR ISOQUINOLINE DERIVATIVES AND SALTS THEREOF | KOWA CO., LTD. (JP) | 2013-06-06 | — | — | US | disclosed |
| US-20130144054-A1 | NOVEL PRODUCTION METHOD FOR ISOQUINOLINE DERIVATIVES AND SALTS THEREOF | KOWA CO., LTD. (JP) | 2013-06-06 | — | — | US | disclosed |
| US-20080064681-A1 | Therapeutic agent for treating glaucoma | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2008-03-13 | — | — | US | disclosed |
| US-20080064681-A1 | Therapeutic agent for treating glaucoma | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2008-03-13 | — | — | US | disclosed |
| US-20070088021-A1 | 4-haloisoquinoline derivative and drug containing the same | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2007-04-19 | — | — | US | disclosed |
| US-20070088021-A1 | 4-haloisoquinoline derivative and drug containing the same | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130144054-A1 | NOVEL PRODUCTION METHOD FOR ISOQUINOLINE DERIVATIVES AND SALTS THEREOF | NOS2, NOS3, NOS1 | SYK 2477/4885BACE1 1409/4885CTSK 1583/4885 |
| US-20080064681-A1 | Therapeutic agent for treating glaucoma | PDE6G, PDE3A, PDE5A | SYK 4481/4885BACE1 3546/4885CTSK 852/4885 |
| US-20070088021-A1 | 4-haloisoquinoline derivative and drug containing the same | ROCK1, CIT, ROCK2 | SYK 1166/4885BACE1 3857/4885CTSK 2568/4885 |
| US-20150087824-A1 | NOVEL PRODUCTION METHOD FOR ISOQUINOLINE DERIVATIVES AND SALTS THEREOF | NOS2, NOS3, NOS1 | SYK 2477/4885BACE1 1409/4885CTSK 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.